

**COMPLETE LIST OF CLAIMS**

C1  
Claim 1 (amended) Therapeutic compositions for the symptomatic relief of cough associated with respiratory tract conditions resulting from the common cold, bronchial asthma, and acute and chronic bronchitis in warm-blooded animals in need of such treatment said compositions comprising pharmaceutically effective amounts of active ingredients, said active ingredients consisting of carbetapentane tannate and guaifenesin.

Claim 2 (previously presented) A therapeutic composition as claimed in claim 1 in tablet form. ✓

Claim 3 (previously presented) A therapeutic composition as claimed in claim 1 in suspension form. ✓

Claim 4 (amended) A method for symptomatically treating and relieving the distress of cough associated with respiratory tract conditions resulting from the common cold, bronchial asthma, and acute and chronic bronchitis in warm-blooded animals which comprises orally administering to warm-blooded animals in need of such treatment a therapeutic amount of a composition comprising pharmaceutically effective amounts of active ingredients, said active ingredients consisting of carbetapentane tannate and guaifenesin.

Claim ~~5~~ (previously presented) A method as claimed in claim 4 wherein said composition is in tablet form.

Claim 6 (previously presented) A method as claimed in claim 4 wherein said composition is a suspension.

Claims 7-14 (cancelled)

CI  
com  
Claim 15 (previously presented) Therapeutic compositions for the symptomatic relief of cough associated with respiratory tract conditions resulting from the common cold, bronchial asthma, and acute and chronic bronchitis, in warm-blooded animals in need of such treatment, said compositions comprising in tablet form pharmaceutically effective amounts of active ingredients and a pharmaceutically suitable carrier, said active ingredients consisting of carbetapentane tannate in an amount of from about 50 mg. to about 75 mg., per tablet, and guaifenesin in an amount of from about 100 mg. to about 300 mg., per tablet.

Claim 16 (previously presented) The therapeutic compositions of claim 15, wherein said tablets contain about 60 mg. of carbetapentane tannate, per tablet, and about 200 mg. of guaifenesin, per tablet.

Claim 17 (previously presented) Therapeutic compositions for the symptomatic relief of cough associated with respiratory tract conditions resulting from the common

cold, bronchial asthma, and acute and chronic bronchitis, in warm-blooded animals in need of such treatment, said compositions comprising a pharmaceutically effective amount of active ingredients suspended in a pharmaceutically suitable liquid carrier, said active ingredients consisting of carbetapentane tannate in an amount of from about 20 mg. to about 40 mg., per 5 ml. of suspension, and guaifenesin in an amount of from about 50 mg. to about 150 mg., per 5 ml. of suspension.

Claim 18 (previously presented) The therapeutic compositions of claim 17, wherein said suspensions contain about 30 mg. of carbetapentane tannate, per 5 ml. of suspension, and about 100 mg. of guaifenesin, per 5 ml. of suspension.

C  
com.  
Claim 19 (previously presented) A method for symptomatically treating and relieving the distress of cough associated with respiratory tract conditions resulting from the common cold, bronchial asthma, and acute and chronic bronchitis, in warm-blooded animals which comprises orally administering to warm-blooded animals in need of such treatment a therapeutic amount of a composition comprising in tablet form pharmaceutically effective amounts of active ingredients and a pharmaceutically suitable carrier, said active ingredients consisting of carbetapentane tannate in an amount of from about 50 mg. to about 75 mg., per tablet, and guaifenesin in an amount of about 100 mg. to about 300 mg. guaifenesin, per tablet.

Claim 20 (previously presented) The method of claim 19 wherein said tablets contain about 60 mg. of carbetapentane tannate, per tablet, and about 200 mg. of

guaifenesin, per tablet.

21  
com

Claim 21 (previously presented) A method for symptomatically treating and relieving the distress of cough associated with respiratory tract conditions resulting from the common cold, bronchial asthma, and acute and chronic bronchitis, in warm-blooded animals which comprises orally administering to warm-blooded animals in need of such treatment a therapeutic amount of a composition comprising a pharmaceutically effective amount of active ingredients suspended in a pharmaceutically suitable liquid carrier, said active ingredients consisting of carbetapentane tannate in an amount of from about 20 mg. to about 40 mg., per 5 ml. of suspension, and guaifenesin in an amount of from about 50 mg. to about 150 mg., per 5 ml. of suspension.

Claim 22 (previously presented) The method of claim 21 wherein said suspension form contains about 30 mg. of carbetapentane tannate, per 5 ml. of suspension, and about 100 mg. of guaifenesin, per 5 ml. of suspension.

12

Claim 23 (new) Twice-a-day therapeutic compositions for the symptomatic relief of cough associated with respiratory tract conditions resulting from the common cold, bronchial asthma, and acute and chronic bronchitis, in warm-blooded animals in need of such treatment, said compositions comprising in tablet form pharmaceutically effective amounts of active ingredients and a pharmaceutically suitable carrier, said active ingredients consisting of carbetapentane tannate in an amount of from about 50 mg. to about 75 mg., per tablet, and guaifenesin in an amount of from about 100 mg. to about

300 mg., per tablet.

Claim 24 (new) The therapeutic compositions of claim 23, wherein said tablets contain about 60 mg. of carbetapentane tannate, per tablet, and about 200 mg. of guaifenesin, per tablet.

C2  
Com.  
Claim 25 (new) Twice-a-day therapeutic compositions for the symptomatic relief of cough associated with respiratory tract conditions resulting from the common cold, bronchial asthma, and acute and chronic bronchitis, in warm-blooded animals in need of such treatment, said compositions comprising a pharmaceutically effective amount of active ingredients suspended in a pharmaceutically suitable liquid carrier, said active ingredients consisting of carbetapentane tannate in an amount of from about 20 mg. to about 40 mg., per 5 ml. of suspension, and guaifenesin in an amount of from about 50 mg. to about 150 mg., per 5 ml. of suspension.

Claim 26 (new) The therapeutic compositions of claim 25, wherein said suspensions contain about 30 mg. of carbetapentane tannate, per 5 ml. of suspension, and about 100 mg. of guaifenesin, per 5 ml. of suspension.

Claim 27 (new) A method for symptomatically treating and relieving the distress of cough associated with respiratory tract conditions resulting from the common cold, bronchial asthma, and acute and chronic bronchitis, in warm-blooded animals which comprises orally administering to warm-blooded animals in need of such treatment a

therapeutic amount of a composition comprising in tablet form pharmaceutically effective amounts of active ingredients and a pharmaceutically suitable carrier, said active ingredients consisting of carbetapentane tannate in an amount of from about 50 mg. to about 75 mg., per tablet, and guaifenesin in an amount of about 100 mg. to about 300 mg. guaifenesin, per tablet, twice-a-day.

Claim 28 (new) The method of claim 27 wherein said tablets contain about 60 mg. of carbetapentane tannate, per tablet, and about 200 mg. of guaifenesin, per tablet.

C2  
Cem  
Claim 29 (new) A method for symptomatically treating and relieving the distress of cough associated with respiratory tract conditions resulting from the common cold, bronchial asthma, and acute and chronic bronchitis, in warm-blooded animals which comprises orally administering to warm-blooded animals in need of such treatment a therapeutic amount of a composition comprising a pharmaceutically effective amount of active ingredients suspended in a pharmaceutically suitable liquid carrier, said active ingredients consisting of carbetapentane tannate in an amount of from about 20 mg. to about 40 mg., per 5 ml. of suspension, and guaifenesin in an amount of from about 50 mg. to about 150 mg., per 5 ml. of suspension, twice-a-day.

Claim 30 (new) The method of claim 29 wherein said suspension form contains about 30 mg. of carbetapentane tannate, per 5 ml. of suspension, and about 100 mg. of guaifenesin, per 5 ml. of suspension.

---